Skip to main content
Type at least 3 characters

1,513 articles

articles

Brief Research Report

Published on 01 Feb 2023

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

in Multiple Sclerosis and Neuroimmunology

  • Pilar Santiago-Setien
  • Cristina BarquĂ­n-Rego
  • Paula Hernández-MartĂ­nez
  • MarĂ­a Ezquerra-Marigomez
  • Marta Torres-Barquin
  • Cristina MenĂ©ndez-Garcia
  • Fernando Uriarte
  • YĂ©sica JimĂ©nez-LĂłpez
  • Mercedes Misiego
  • Jose RamĂłn Sánchez de la Torre
Frontiers in Immunology
doi 10.3389/fimmu.2023.1086028
  • 8,510 views
  • 6 citations